Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".

Abstract

In February 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) had recommended the suspension of efalizumab's (Raptiva) marketing authorization, because its benefits in the treatment of psoriasis were modest, while there was a risk of serious side effects in patients receiving the medicine, including the occurrence of progressive multifocal leukoencephalopathy (PML). The guideline group has changed the guideline accordingly.

• Authors: Alexander Nast, Matthias Augustin, Wolf-Henning Boehncke, Joachim Klaus, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Martin Schlaeger, Michael Sebastian, Wolfram Sterry, Volker Streit, Peter Weisenseel, Berthold Rzany
• Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG (J Dtsch Dermatol Ges) Vol. 8 Issue 1 Pg. 65-6 (Jan 2010) ISSN: 1610-0387 [Electronic] Germany
• PMID: 20096063 (Publication Type: Journal Article, Practice Guideline)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• efalizumab

Topics

• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Dermatology (standards)
• European Union
• Evidence-Based Medicine
• Humans
• Practice Guidelines as Topic
• Psoriasis (drug therapy)